Templates Inc Announces Proposed Public Offering of Common Stock
Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-degree oncology corporation focused at the discovery and improvement of proprietary engineered toxin bodies (ETBs), which might be differentiated, centered, biologic therapeutics for most cancers, these days announced that it intends to offer and promote, difficulty to market and different situations, $30 million of its shares of commonplace stock in an underwritten public presenting. Molecular also intends to grant the underwriters a 30-day option to buy up to an extra 15% of the stocks of commonplace inventory supplied within the public imparting on the equal terms and situations. All of the shares inside the presenting are to be sold with the aid of Molecular.
Molecular intends to apply the net proceeds from the offering, together with its existing cash and coins equivalents, to fund: its ongoing Phase Ib and Phase II medical studies and deliberate additional Phase II scientific research for MT-3724 in DLBCL; its percentage of development prices in its CD38 collaboration with Takeda; its programs concentrated on HER2 and PD-L1; further preclinical development and drug discovery activities in its other applications and for running capital and fashionable company functions. The offering is difficult to market and different situations, and there may be no guarantee as to whether or when the providing can be finished, or as to the real length or phrases of the imparting.
Cowen, Evercore ISI, and UBS Investment Bank are acting as joint ebook-strolling managers for the providing. Laidlaw & Company (UK) Ltd. Is acting as lead supervisor for the supplying.
The stocks are being offered by way of Molecular pursuant to a shelf registration assertion on Form S-three that became formally filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective by way of the SEC. A preliminary prospectus supplement regarding the supplying can be filed with the SEC. When to be had, copies of the initial prospectus supplement and the accompanying prospectus relating to these securities can be acquired from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or with the aid of telephone at (631) 274-2806; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, thirty sixth Floor, New York, NY 10055, through cellphone at 888-474-0200, or by email at [email protected] or UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, through telephone at 1-888-827-7275 or by means of emailing [email protected] You may also attain those files free of price by way of traveling the SEC’s website at www.Sec.Gov.
This press release does no longer represent a proposal to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any kingdom or jurisdiction in which such a proposal, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of one of this country or jurisdiction.
This press release consists of ahead-looking statements for functions of the Private Securities Litigation Reform Act of 1995 (the “Act”). Molecular disclaims any reason or obligation to replace these forward-looking statements and claims the safety of the Act’s Safe Harbor for forward-searching statements. All statements, other than statements of ancient information, protected in this press launch regarding strategy, future operations, future economic function, future sales, projected costs, prospects, plans and objectives of management are forward-looking statements. In addition, while or if used on this press release, the words “may also,” “ought to,” “need to,” “count on,” “trust,” “estimate,” “count on,” “intend,” “plan,” “predict” and comparable expressions and their versions, as they relate to Molecular, may perceive forward-searching statements. Examples of such statements encompass but are not constrained to, statements relating to Molecular’s expectations with respect to its proposed providing, Molecular’s expectations with admire to its collaboration with Takeda, its goal to supply the underwriters an option to purchase additional shares and its supposed use of proceeds from the proposed providing.
Forward-searching statements are not ensured of destiny overall performance and contain dangers and uncertainties. Actual occasions or outcomes can also range materially from those discussed in the ahead-searching statements because of different factors together with, but no longer constrained to, the uncertainties inherent within the preclinical and clinical development technique; whether or not the Company’s coins assets may be enough to fund its persevering with operations for the intervals and/or trials predicted; the potential of the Company to shield its intellectual belongings rights; and legislative, regulatory, political and financial trends, as well as the ones risks identified underneath the heading “Risk Factors” within the Company’s filings with the SEC. Any forward-searching statements contained on this press release talk simplest as of the date hereof, and the Company specifically disclaims any duty to update any forward-searching statement, whether because of new facts, destiny occasions or in any other case.